June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data
Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to treat insomnia. The OX2R antagonist is partnered with Johnson & Johnson (NYSE:JNJ). Minerva is up $1.34 (32%) to $5.57 since reporting the data, despite giving back some of its gains Tuesday.

Aldeyra falls on Phase III miss
Aldeyra Therapeutics Inc. (NASDAQ:ALDX) lost $0.88 (12%) to $6.21 Tuesday after announcing it would discontinue its non-infectious anterior uveitis program after reproxalap (ADX-102) missed the primary and secondary endpoints in the Phase III SOLACE trial in the indication due to high rates of disease resolution in vehicle-treated patients. In May, the small molecule, which covalently binds and traps free aldehydes, met the endpoints in the Phase III ALLEVIATE trial and is in Phase III testing for dry eye disease and Sjögren-Larsson syndrome (see "Allergic Conjunctivitis Therapy Clears Phase III Hurdle")...